PegBio (HKG:2565) booked 208.4 million yuan in attributable loss for 2025, narrowing from 283.4 million yuan in 2024, according to a Hong Kong bourse filing Monday.
Loss per share was 0.55 yuan, compared with 0.77 yuan in the prior year.
The firm did not generate any revenue during the year or in 2024.